ArticleBMC pharmacology & toxicology2025
Development and validation of a UPLC-MS/MS method for the quantification of asciminib and its pharmacokinetic interaction and metabolic stability with shikonin.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asciminib has been approved for use in patients with chronic myeloid leukemia (CML) in the chronic phase. Shikonin has multiple pharmacological effects and is a mixed inhibitor of CYP450 enzymes. In clinical practice, the combination of asciminib and shikonin may lead to drug interactions. This study developed and validated a highly efficient and accurate ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the quantitative determination of asciminib and investigated the interaction between asciminib and shikonin. Chromatographic separations of asciminib and fluconazole (internal standard, IS) were accomplished by a 2.0-min gradient elution with acetonitrile and water (with 0.1% formic acid) as the mobile phase. Quantification was conducted in positive ion mode with multiple reaction monitoring (MRM). The results showed that the linear correlation of asciminib was satisfactory within 5-1000 ng/mL with a lower limit of quantification (LLOQ) of 5 ng/mL. Moreover, the validation of required recoveries, precision, accuracy, stability, and matrix effects were achieved in accordance with FDA guidelines. Subsequently, the interaction between asciminib and shikonin in rats was investigated. Pharmacokinetic results showed that shikonin reduced the CLz/F and increased the AUC(0−t). Metabolic stability results showed that shikonin significantly prolonged the in vitro t1/2 from 178.9 ± 14.0 to 748.0 ± 208.7 min and significantly reduced intrinsic clearance (Clint) from 12.9 ± 1.0 to 3.1 ± 0.8 µL/min/mg protein. The UPLC-MS/MS method established in this experiment was confirmed to be capable of accurately quantifying asciminib and was successfully used in both in vivo and in vitro studies of asciminib in combination with shikonin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.